Finch’s leading donor program and manufacturing capabilities will enable rapid scale-up upon commercialization of its Full-Spectrum Microbiota™ products. Through its collaboration with OpenBiome, products manufactured by Finch are distributed to a network of more than 900 providers. Overall, 88% of patients achieved clinical success, defined as no recurrence of CDI over two months.įinch currently operates one of the largest stool donation programs in the world and manufactures approximately 1,000 microbial treatments every month. Khoruts’ clinical team administered their product in a single center, open label study of 49 patients with recurrent CDI. As published in The American Journal of Gastroenterology, Dr. Michael Sadowsky, who developed a leading early-stage oral formulation of a microbiota-based product in 2014. PRISM 3 builds on the clinical success of Crestovo’s academic collaborators, Dr. CP101 is being evaluated in PRISM 3, a 240-patient, placebo-controlled trial. ![]() Borody has made significant contributions to the company’s IP portfolio, including several patent families with priority dates as early as 2000.ĬP101, an encapsulated, orally-administered, Full-Spectrum Microbiota™ product containing microbiota harvested from healthy human donors, is Crestovo’s potentially first-in-class treatment for patients with recurrent C. “Finch is positioned as the partner of choice for researchers in this field.” Dr. “After more than three decades of clinical research on microbial therapies, I am thrilled that Finch Therapeutics Group is bringing together the critical components needed to scale this new class of medicine,” commented Tom Borody, M.D., an early pioneer of microbial therapeutics and a scientific co-founder joining Finch from Crestovo. At the same time, we continue to expand our pipeline of wholly-owned candidates for diseases impacted by the microbiome.” We are also leveraging our human-first discovery and machine-learning platform to develop Rationally-Selected Microbiota™ therapies for inflammatory bowel disease through our partnership with Takeda. Joseph Lobacki, COO of Finch Therapeutics Group added, “Finch Therapeutics Group is differentiated by our unique commercial-scale manufacturing operations, which through a collaboration with OpenBiome, already delivers microbiome treatments to thousands of patients each year. difficile infections, we look forward to accelerating the development of this important new class of therapy.” “With the network of collaborators from both companies driving patient recruitment in PRISM 3, an ongoing 240-patient placebo-controlled trial of CP101 in recurrent C. difficile infections with a novel technology platform for developing Rationally-Selected Microbiota™ products uniquely positions Finch Therapeutics Group to deliver on both the near- and long-term promise of microbiome therapies to transform public health and quickly reach the patient populations we yearn to serve,” said Mark Smith, Ph.D., CEO of Finch Therapeutics Group. “This combination of a potential first-in-class product candidate for recurrent C. The new company is headquartered in Somerville and led by Chief Executive Officer Mark Smith, Ph.D., previously Finch’s President and Chief Executive Officer, and Chief Operating Officer Joseph Lobacki, previously Chief Operating Officer and interim CEO of Crestovo. ![]() ![]() difficile infections, CP101, an oral Full-Spectrum Microbiota™ product, with Finch’s commercial-scale manufacturing capabilities, discovery platform for developing Rationally-Selected Microbiota™ and significant product pipeline. The new entity, Finch Therapeutics Group, combines Crestovo’s extensive IP assets and late-stage candidate for recurrent C. SOMERVILLE, MA & CAMBRIDGE, MA, USA I OctoI Finch Therapeutics, a privately held microbiome engineering company and Crestovo, a privately held, clinical-stage biopharmaceutical company, announced today the successful completion of a merger, creating a leading, fully integrated microbiome company. ![]() Merged entity includes a diverse pipeline of Full-Spectrum Microbiota™ and Rationally-Selected Microbiota™ products, an innovative discovery platform, large-scale manufacturing capabilities and a broad IP portfolio
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |